Clonal Origin of Hepatocellular Carcinoma and Recurrence After Liver Transplantation

被引:4
|
作者
Wang, Zhenglu [1 ,2 ,3 ]
Gong, Weihua [4 ]
Shou, Dawei [4 ]
Zhang, Luzhou [5 ]
Gu, Xiangqian [6 ]
Wang, Yuliang [2 ]
Teng, Dahong [1 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Tianjin First Ctr Hosp, Orient Organ Transplant Ctr, Tianjin, Peoples R China
[2] Tianjin First Ctr Hosp, Key Lab Crit Care Med, Minist Hlth, Tianjin, Peoples R China
[3] Tianjin Key Lab Organ Transplantat, Tianjin, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Surg, Hangzhou, Zhejiang, Peoples R China
[5] Peoples Hosp Zhucheng City, Zhucheng, Shandong, Peoples R China
[6] Tianjin Med Univ, Cent Clin Inst 1, Tianjin, Peoples R China
关键词
Carcinoma; Hepatocellular; Liver Transplantation; Loss of Heterozygosity; Neoplasm Recurrence; Local; CANCER STEM-CELLS; INTRAHEPATIC METASTASIS; MULTICENTRIC ORIGIN; HETEROZYGOSITY; MULTIPLE; RESECTION; HEPATOCARCINOGENESIS; MICROSATELLITES; SURVIVAL;
D O I
10.12659/AOT.899572
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: This study aimed to determine whether patterns of tumor clonal origin in pluri-nodular hepatocellular carcinoma (PNHC) could serve as an indicator of tumor recurrence following liver transplantation. Material/Methods: Tumor tissue samples from 60 PNHC patients who underwent liver transplantation were examined. The diagnosis of patients conformed to the University of California San Francisco (UCSF) standards for pluri-nodular hepatocellular carcinoma. We performed loss of heterozygosity tests at multiple microsatellite sites to determine the clonal origins of the tumors. Clinical information, pathological data, preoperative serum alpha-feto protein (AFP) and postoperative follow-ups were obtained and correlations between the clonal origin of the tumor, tumor-free survival, pathological characteristics, and AFP levels in serum were studied. Results: A total of 165 tumor nodules were collected. Tumor clonal origins were identified as intrahepatic metastasis (IM; 41.67%), multicentric occurrence (MO; 55%) or unidentified (3.33%). Three-year tumor-free survival for the IM group was 48% compared to 75.76% in the MO group (p<0.05), while the occurrence of microscopic tumor thrombus was 100% and 3.03% (p<0.05) for these groups, respectively. The degree of tumor differentiation was 80% for the IM group and 18.18% for the MO group (p<0.05), while the mean AFP concentration for these groups was 226.80 mu g/L (2.78-3000 mu g/L) and 24.59 mu g/L (1.16-531. 30 mu g/L; p<0.05), respectively. Conclusions: Clonal origin patterns can serve as important indicators to predict the recurrence of PNHC following liver transplantation. Taken together with pathological characteristics and preoperative serum AFP levels, the risk of recurrence can be established in advance.
引用
收藏
页码:484 / 490
页数:7
相关论文
共 50 条
  • [21] Needle tract recurrence of hepatocellular carcinoma after liver transplantation
    Dumortier, J
    Lombard-Bohas, C
    Valette, PJ
    Boillot, O
    Scoazec, JY
    Berger, F
    Claudel-Bonvoisin, S
    GUT, 2000, 47 (02) : 301 - 301
  • [22] Recurrence of hepatocellular carcinoma as a mixed hepatoblastoma after liver transplantation
    Dumortier, J
    Bizollon, T
    Chevallier, M
    Ducerf, C
    Baulieux, J
    Scoazec, JY
    Trepo, C
    GUT, 1999, 45 (04) : 622 - 625
  • [23] Effect of everolimus on hepatocellular carcinoma recurrence after liver transplantation
    Joo, D. J.
    Lee, J. J.
    Kim, D. G.
    Lee, J. G.
    Lee, J.
    Kim, S. H.
    Han, D. H.
    Lee, H. S.
    Ju, M. K.
    Choi, G. H.
    Choi, J. S.
    Kim, M. S.
    Kim, S., I
    TRANSPLANTATION, 2019, 103 (08) : 54 - 55
  • [24] Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
    Fernandez-Sevilla, Elena
    Allard, Marc-Antoine
    Selten, Jasmijn
    Golse, Nicolas
    Vibert, Eric
    Cunha, Antonio Sa
    Cherqui, Daniel
    Castaing, Denis
    Adam, Rene
    LIVER TRANSPLANTATION, 2017, 23 (04) : 440 - 447
  • [25] Antiplatelet Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation
    Choi, Mun Chae
    Min, Eun-Ki
    Lee, Jae Geun
    Joo, Dong Jin
    Kim, Myoung Soo
    Kim, Deok-Gie
    CANCERS, 2022, 14 (21)
  • [26] Impact of Sirolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation
    Chinnakotla, Srinath
    Davis, Gary L.
    Vasani, Sugam
    Kim, Peter
    Tomiyama, Koji
    Sanchez, Edmund
    Onaca, Nicholas
    Goldstein, Robert
    Levy, Marlon
    Klintmalm, Goeran B.
    LIVER TRANSPLANTATION, 2009, 15 (12) : 1834 - 1842
  • [27] EVEROLIMUS AND SORAFENIB FOR RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    De Simone, Paolo
    Pezzati, Daniele
    Lai, Quirino
    Ghinolfi, Davide
    Coletti, Laura
    Precisi, Arianna
    Leonardi, Giulia
    Carrai, Paola
    Filipponi, Franco
    TRANSPLANT INTERNATIONAL, 2013, 26 : 293 - 293
  • [28] A MODEL TO PREDICT RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    Foxton, Matthew R.
    Sutcliffe, Robert P.
    Portmann, Bernard C.
    Heaton, Nigel
    O'Grady, John G.
    HEPATOLOGY, 2010, 52 (04) : 862A - 862A
  • [29] Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
    Kim, Jong Man
    CLINICAL AND MOLECULAR HEPATOLOGY, 2021, 27 (04) : 562 - 563
  • [30] Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation
    Schlitt, HJ
    Neipp, M
    Weimann, A
    Oldhafer, KJ
    Schmoll, E
    Boeker, K
    Nashan, B
    Kubicka, S
    Maschek, H
    Tusch, G
    Raab, R
    Ringe, B
    Manns, MP
    Pichlmayr, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 324 - 331